Iclusig 15 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DR26FMDY1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,287
Award facts
- Contract value 100% obligated
- $29,286.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,286.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for ICLUSIG 15 mg tablets (30-count). The delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V prime contract, awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The company serves as a regional prime vendor contractor within this broader strategic sourcing initiative, authorized to provide firm fixed-price delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. This delivery order for ICLUSIG, an oncology treatment, exemplifies DMS Pharmaceutical Group's role as a critical supplier supporting the specialized pharmaceutical requirements of the military medical system, with the company demonstrating consistent contract performance across multiple therapeutic categories and product lines.
Quick answers
Who was awarded contract SPE2DR26FMDY1?
SPE2DR26FMDY1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FMDY1 worth?
The government has obligated $29,287 on SPE2DR26FMDY1.
Is contract SPE2DR26FMDY1 an order under another contract?
Yes. SPE2DR26FMDY1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDY1 competed?
The extent of competition for SPE2DR26FMDY1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award